BioCryst Pharmaceuticals (BCRX) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 3[1], 2 Phase 1[2].
Trial NCT04933721[4] evaluates berotralstat in Hereditary Angioedema with a target enrollment of 139 participants. Trial NCT05453968[5] evaluates Berotralstat in Hereditary Angioedema with a target enrollment of 29 participants.
BCRX has 3 Form 4 insider filings recorded at the SEC in the past 30 days[6].